Lifesci Capital Has Bullish Estimate for DYN Q1 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Research analysts at Lifesci Capital boosted their Q1 2026 earnings per share estimates for shares of Dyne Therapeutics in a research report issued to clients and investors on Monday, March 2nd. Lifesci Capital analyst F. Brisebois now expects that the company will post earnings per share of ($0.76) for the quarter, up from their prior estimate of ($0.77). The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. Lifesci Capital also issued estimates for Dyne Therapeutics’ Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.83) EPS and Q4 2026 earnings at ($0.86) EPS.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02).

Several other research analysts have also weighed in on the stock. HC Wainwright lowered their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday. Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $11.00 to $40.00 in a research note on Wednesday, December 10th. Wall Street Zen downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, January 21st. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $40.00 price objective on shares of Dyne Therapeutics in a research report on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $15.20 on Thursday. The company has a market capitalization of $2.51 billion, a PE ratio of -4.29 and a beta of 1.34. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $25.00. The company has a 50-day simple moving average of $17.15 and a 200-day simple moving average of $17.03. The company has a quick ratio of 13.47, a current ratio of 22.25 and a debt-to-equity ratio of 0.15.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC acquired a new position in shares of Dyne Therapeutics in the 3rd quarter worth approximately $30,000. Strs Ohio bought a new position in Dyne Therapeutics during the fourth quarter worth $51,000. CWM LLC boosted its holdings in Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after purchasing an additional 1,900 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics in the fourth quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC increased its stake in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained a $50 price target while publishing quarter-by-quarter EPS forecasts that are in line with management’s cadence — this is supportive for longer‑term sentiment. HC Wainwright reiterates Buy, $50 PT
• Positive Sentiment: Lifesci Capital nudged up its Q1 and Q3 2026 EPS forecasts slightly (Q1: from -$0.77 to -$0.76; Q3: from -$0.85 to -$0.83), signaling modestly improved near-term expectations from that shop. Lifesci raises Q1 & Q3 forecasts
• Neutral Sentiment: Reported short interest data for early March is effectively zero/indeterminate (entry shows 0 shares and NaN change), so short-covering or large new shorts are not a current driver based on that release.
• Neutral Sentiment: Several small, offsetting analyst estimate moves from Lifesci Capital (Q2 and Q4 nudged slightly lower while other quarters nudged higher) leave the consensus full‑year loss estimate unchanged at roughly -$3.44, implying no material change to the broad street view. Lifesci mixed estimate revisions
• Negative Sentiment: Investors reacted to the company’s latest quarterly result, which missed EPS expectations (reported -$0.76 vs. consensus -$0.74), prompting an immediate negative move in the stock. Stock down after disappointing earnings
• Negative Sentiment: Lifesci Capital lowered its Q4 2026 EPS forecast slightly (from -$0.85 to -$0.86) and trimmed other quarter forecasts overall, reflecting modest downward revisions to near‑term profitability expectations. Lifesci lowers Q4 forecast

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.